

Reference:	FOI.10275.22
Subject:	Procurement and use of nPlate (Romiplostim)
Date of Request:	14 November 2022

Requested:

Please can you provide the following information on the Hywel Dda University Health Board purchases of the Drug named "nPlate (Romiplostim)".

1. Who at the Hywel Dda University Health Board authorised the use and purchase of the drug nPlate (Romiplostim).
2. The name of the Departments who utilised the nPlate (Romiplostim) and under which Project or Department requests.
3. The exact amounts of the nPlate (Romiplostim) purchased, and the Batch numbers of the nPlate (Romiplostim) purchased.
4. Also of the name of the Company that supplied the nPlate (Romiplostim) to Hywel Dda University. Also the dates when the Health authority started using nPlate (Romiplostim)?

Response:

1. Hywel Dda University Health Board (UHB) does not hold all of the information requested, due to the time that has passed since its recommendation for use. However, the UHB can confirm that Romiplostim was recommended for use by the National Institution of Health and Care Excellence (NICE) under reference TA221 in April 2011, and so would have been made available for use under the processes in place at the time, as defined by the Drugs and Therapeutics Committee.
2. A breakdown of the wards and departments which have issued Romiplostim to patients is provided within Attachment 1.
3. The UHB has provided the quantity of Romiplostim purchased by it within Attachment 2. Unfortunately, it is not possible to provide you with the batch numbers as these are not routinely recorded on the pharmaceutical system.
4. Amgen is the UHB's supplier of Romiplostim, with the first issue being made in September 2011.